Evidence map›Paper›PMID 40996483›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Do we need a health technology assessment approach for non-inferiority specifically? A comment on: clinical equivalence and non-inferiority within health technology assessment by Taylor et al. (2025).

Beryl Primrose Gladstone, Werner Vach

Abstract readLetter
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Beryl Primrose GladstoneInfectious diseases Division, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany. primrose.beryl@med.uni-tuebingen.de.ORCID http://orcid.org/0000-0002-4733-5890
Werner VachBasel Academy for Quality and Research in Medicine, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Taylor and colleagues presented a very informative and comprehensive overview on the current practice of performing non-inferiority analysis in HTA. We would like to point out that HTA of potentially non-inferior technologies should be based on balancing potential advantages against potential deficits exactly as for potentially superior technologies.

Indexed as

Equivalence Trials as TopicTechnology Assessment, BiomedicalCost-Benefit AnalysisHumansTherapeutic EquivalencyAdvantage deficit assessmentHealth technology assessmentNon-inferiorityNon-inferiority margin

Identifiers

PMID40996483
PMCPMC12929271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.